Wright JE - Search Results

1

Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute lymphocytic leukemia.

Trippett T, Schlemmer S, Elisseyeff Y, Goker E, Wachter M, Steinherz P, Tan C, Berman E, Wright JE, Rosowsky A, et al. Trippett T, et al. Among authors: wright je. Blood. 1992 Sep 1;80(5):1158-62. Blood. 1992. PMID: 1381235 Free article.

2

Elevated dihydrofolate reductase and impaired methotrexate transport as elements in methotrexate resistance in childhood acute lymphoblastic leukemia.

Matherly LH, Taub JW, Ravindranath Y, Proefke SA, Wong SC, Gimotty P, Buck S, Wright JE, Rosowsky A. Matherly LH, et al. Among authors: wright je. Blood. 1995 Jan 15;85(2):500-9. Blood. 1995. PMID: 7812005 Free article.

3

Influence of lipophilicity and carboxyl group content on the rate of hydroxylation of methotrexate derivatives by aldehyde oxidase.

Rosowsky A, Wright JE, Holden SA, Waxman DJ. Rosowsky A, et al. Among authors: wright je. Biochem Pharmacol. 1990 Aug 15;40(4):851-7. doi: 10.1016/0006-2952(90)90326-g. Biochem Pharmacol. 1990. PMID: 1696821

4

Wild-type and drug-resistant Leishmania major hydrolyze methotrexate to N-10-methyl-4-deoxy-4-aminopteroate without accumulation of methotrexate polyglutamates.

Ellenberger TE, Wright JE, Rosowsky A, Beverley SM. Ellenberger TE, et al. Among authors: wright je. J Biol Chem. 1989 Sep 25;264(27):15960-6. J Biol Chem. 1989. PMID: 2476435 Free article.

5

Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.

Chen G, Wright JE, Rosowsky A. Chen G, et al. Among authors: wright je. Mol Pharmacol. 1995 Oct;48(4):758-65. Mol Pharmacol. 1995. PMID: 7476904

6

Methotrexate and gamma-tert-butyl methotrexate transport in CEM and CEM/MTX human leukemic lymphoblasts.

Wright JE, Rosowsky A, Cucchi CA, Flatow J, Frei E 3rd. Wright JE, et al. Biochem Pharmacol. 1993 Sep 1;46(5):871-6. doi: 10.1016/0006-2952(93)90496-j. Biochem Pharmacol. 1993. PMID: 8373437

7

Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues.

Wright JE, Vaidya CM, Chen Y, Rosowsky A. Wright JE, et al. Biochem Pharmacol. 2000 Jul 1;60(1):41-6. doi: 10.1016/s0006-2952(00)00294-x. Biochem Pharmacol. 2000. PMID: 10807943

8

Synthesis and enzymatic activation of N-[N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithiny]-L-phenylalanine, a candidate for antibody-directed enzyme prodrug therapy (ADEPT).

Wright JE, Rosowsky A. Wright JE, et al. Bioorg Med Chem. 2002 Mar;10(3):493-500. doi: 10.1016/s0968-0896(01)00298-x. Bioorg Med Chem. 2002. PMID: 11814834

9

Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells.

Rhee MS, Galivan J, Wright JE, Rosowsky A. Rhee MS, et al. Among authors: wright je. Mol Pharmacol. 1994 Apr;45(4):783-91. Mol Pharmacol. 1994. PMID: 7514264

10

Collateral methotrexate resistance in cultured human head and neck carcinoma cells selected for resistance to cis-diamminedichloroplatinum(II).

Rosowsky A, Wright JE, Cucchi CA, Flatow JL, Trites DH, Teicher BA, Frei E 3rd. Rosowsky A, et al. Among authors: wright je. Cancer Res. 1987 Nov 15;47(22):5913-8. Cancer Res. 1987. PMID: 3664492

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

453 results

Search Page

Filters